Cagrilintide

Cagrilintide is a synthetic, long-acting analogue of amylin, a 37 amino acid pancreatic peptide hormone co-secreted with insulin from the beta cells of the pancreas in response to food intake ^[5]. Native amylin is prone to forming amyloid fibrils, which makes it difficult to develop as a drug; cagrilintide was engineered through lipidation and sequence modification to create a stable, soluble molecule with a long half-life suitable for once-weekly subcutaneous administration ^[3]. It acts as a dual agonist at amylin and calcitonin receptors, and it was developed by Novo Nordisk as a weight-management agent ^[4].

Amylin physiology places cagrilintide within the gut-brain axis of appetite regulation. The hormone signals satiety through both homeostatic and hedonic regions of the brain, slows gastric emptying, and reduces food intake ^[4][5]. Cagrilintide extends these effects across a full week, and it is frequently studied in combination with the GLP-1 receptor agonist semaglutide, a pairing known as CagriSema that targets two complementary satiety pathways at once ^[2][4].

Research applications center on obesity and overweight, with clinical programs also examining metabolic and glycemic parameters ^[1][6]. In the pharmacology of obesity, cagrilintide is regarded as part of a new wave of combination and multi-target therapies that aim to close the gap between lifestyle intervention and bariatric surgery ^[6]. Regulatory status is investigational; cagrilintide is not yet an approved standalone medicine and remains in clinical development, typically supplied as a subcutaneous solution for research and trial use ^[3][4].

Cagrilintide is a long-acting amylin analogue in clinical development for weight management; the most common reported effects are gastrointestinal, including nausea, vomiting, constipation and reduced appetite, along with injection-site reactions. As an investigational drug that is not yet approved, its long-term safety is still being established, and because it slows gastric emptying and can affect blood glucose, caution is warranted alongside other glucose-lowering or gastrointestinal-active medications.

Cagrilintide, also designated AM833, is a long-acting amylin analogue engineered by Novo Nordisk as part of its metabolic pipeline, with its side-chain acylation and sequence modifications designed to extend circulation time and prevent the amyloid aggregation that hampered earlier amylin peptides. It advanced through early clinical development in the late 2010s, and a randomized phase 1b trial combining cagrilintide with semaglutide 2.4 mg was published in The Lancet in 2021. The combination, subsequently branded CagriSema, progressed to phase 2 evaluation in type 2 diabetes reported in 2023 and into large phase 3 obesity programs. As a purpose-built modern peptide, its history is well documented in the peer-reviewed clinical literature rather than in older pharmacology.

Cagrilintide is regarded as one of the most promising agents in contemporary metabolic medicine, praised for delivering durable appetite control and meaningful weight loss through a mechanism distinct from GLP-1 drugs. Its standout appeal is additivity: paired with semaglutide it has driven weight reductions substantially greater than either agent alone, which has generated considerable excitement among clinicians and researchers. The once-weekly dosing enabled by its engineered pharmacokinetics adds to its practicality. Discussion generally acknowledges that, like other incretin-class therapies, its most common tolerability issues are gastrointestinal, and that longer phase 3 outcomes continue to define its ultimate place in treatment.